



Prophylactic Therapy in Care Homes Trial-CH (PROTECT-CH)

Health Economic Analysis Dummy Tables and Figures

Authors: Matt Glover (University of Surrey), Heather Gage (University of Surrey)

Approval

Name	Job title	Trial Role	Signature	Date
Philip Bath	Professor of Stroke Medicine	Chief Investigator	PhilyBoth	20/10/2021

Version 1.0 15th October 2021

Version number	Detail of revisions with reason	Initials

List of tables and figures

Table 1: EQ-5D-5L (proxy-report) descriptive system responses at baseline and 60 days post	
randomisation	3
Table 2: EQ-5D-5L (self-report) descriptive system responses at baseline and 60 days post	
randomisation	3
Table 3: EQVAS and EQ-5D-5L utility (proxy-report) at 60 days post randomisation	4
Table 4: EQVAS and EQ-5D-5L utility (self-report) at 60 days post randomisation	4
Table 5: Healthcare resource use unit costs (2019/20 £)	5
Table 6: Healthcare resource use at 60 days post randomisation	5
Table 7: Intervention costs (2019/20 £)	
Table 8: Total healthcare resource use costs at 60 days post randomisation	
Table 9: Cost-effectiveness at 60 days post randomisation	6
Table 10: Cost-effectiveness at 120 days post randomisation	7
Figure 1: EQ-5D-5L (proxy-report) descriptive system responses at 60 days post	
randomisation	3
Figure 2: EQ-5D-5L (self-report) descriptive system responses at 60 days post	
randomisation	4
Figure 3: Healthcare resource use costs at 60 days post randomisation	
Figure 4: Cost-effectiveness plane	
Figure 5: Cost-effectiveness acceptability curve	
rigare 3. cost effectiveness acceptability carve	

Table 1: EQ-5D-5L (proxy-report) descriptive system responses at baseline and 60 days post randomisation

Table 1: EQ-5D-5L (proxy-rep		Usual Care (n=		Intervention Group (n=)		
Treatment A			,	_		<u>, , , , , , , , , , , , , , , , , , , </u>
EQ-5D-5L (proxy-report)	Baseline response	60-day response	Change from baseline %	Baseline response	60-day response	Change from baseline %
Mobility						
No problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderate problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severe problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Unable to walk about	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	
Self-care						
No problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderate problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severe problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Unable to wash or dress	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	
Usual activities						
No problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderate problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severe problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Unable to do usual activities	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	
Pain/discomfort						
No pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderate pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severe pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Extreme pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	
Anxiety/depression						
Not anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slightly anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderately anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severely anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Extremely anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	1

Data are n (%) unless otherwise indicated. Care-home staff directly involved in care giving completed proxy responses.

Figure 1: EQ-5D-5L (proxy-report) descriptive system responses at 60 days post randomisation

Bar chart showing percentages responding to each of 5 levels across dimensions for both groups at baseline and follow-up

Table 2: EQ-5D-5L (self-report) descriptive system responses at baseline and 60 days post randomisation

		Usual Care (n=)	Inte	ervention Group	(n=)
Treatment A						
EQ-5D-5L (self-report)	Baseline response	60-day response	Change from baseline %	Baseline response	60-day response	Change from baseline %
Mobility						
No problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight problems	xx (xx)	xx (xx)	XX	xx (xx)	xx (xx)	xx
Moderate problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severe problems	xx (xx)	xx (xx)	XX	xx (xx)	xx (xx)	xx
Unable to walk about	xx (xx)	xx (xx)	XX	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	XX	
Self-care						
No problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight problems	xx (xx)	xx (xx)	XX	xx (xx)	xx (xx)	xx
Moderate problems	xx (xx)	xx (xx)	XX	xx (xx)	xx (xx)	xx
Severe problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Unable to wash or dress	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	XX	xx		xx	XX	
Usual activities						

No problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderate problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severe problems	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Unable to do usual activities	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	
Pain/discomfort						
No pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slight pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderate pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severe pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Extreme pain/discomfort	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	
Anxiety/depression						
Not anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Slightly anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Moderately anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Severely anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Extremely anxious/depressed	xx (xx)	xx (xx)	xx	xx (xx)	xx (xx)	xx
Missing	xx	xx		xx	xx	

Data are n (%) unless otherwise indicated. Care-home staff directly involved in care giving completed proxy responses.

Figure 2: EQ-5D-5L (self-report) descriptive system responses at 60 days post randomisation

Bar chart showing percentages responding to each of 5 levels across dimensions for both groups at baseline and follow-up

Table 3: EQVAS and EQ-5D-5L utility (proxy-report) at 60 days post randomisation

	Usual Care Group	Intervention Group	Adjusted effect estimate (95% CI)	ICC
Treatment A	(n =)	(n =)		
EQVAS				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25 th , 75 th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	XX	XX		
EQ-5D-5L utility				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25 th , 75 th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	xx	XX		
-				

Table 4: EQVAS and EQ-5D-5L utility (self-report) at 60 days post randomisation

	Usual Care Group	Intervention Group	Adjusted effect estimate (95% CI)	ICC
Treatment A	(n =)	(n =)		
EQVAS				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25 th , 75 th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	XX	XX		
EQ-5D-5L utility				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25 th , 75 th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	xx	xx		

Table 5: Healthcare resource use unit costs (2019/20 £)

Resource use item	Unit cost	Source	Notes
GP (face-to-face)	XX.XX		
GP (remote)	XX.XX		
Nurse (face-to-face)	XX.XX		
Nurse (remote)	XX.XX		
Nurse Specialist (face-to-face)	XX.XX		
Nurse Specialist (remote)	XX.XX		
Allied Health Professional (face-to-face)	XX.XX		
Allied Health Professional (remote)	XX.XX		
Outpatient/hospital doctor	XX.XX		
111 Call	XX.XX		
999 Call	XX.XX		
Ambulance attendance	XX.XX		
A&E attendance (non-admitted)	XX.XX		
A&E attendance (admitted)	XX.XX		
Inpatient admission	XX.XX		
Critical care admission	XX.XX		

Table 6: Healthcare resource use at 60 days post randomisation

	Usual Care Group	Intervention Group	?
Treatment A	(n =)	(n =)	
Resource use item (mean, sd)			
GP face-to-face	xx.xx (xx)	xx.xx (xx)	
GP remote	xx.xx (xx)	xx.xx (xx)	
Nurse face-to-face	xx.xx (xx)	xx.xx (xx)	
Nurse remote	xx.xx (xx)	xx.xx (xx)	
Nurse Specialist face-to-face	xx.xx (xx)	xx.xx (xx)	
Nurse Specialist remote	xx.xx (xx)	xx.xx (xx)	
Allied Health Professional face-to-face	xx.xx (xx)	xx.xx (xx)	
Allied Health Professional remote	xx.xx (xx)	xx.xx (xx)	
Outpatient/hospital doctor	xx.xx (xx)	xx.xx (xx)	
111 Call	xx.xx (xx)	xx.xx (xx)	
999 Call	xx.xx (xx)	xx.xx (xx)	
Ambulance attendance	xx.xx (xx)	xx.xx (xx)	
A&E attendance non-admitted	xx.xx (xx)	xx.xx (xx)	
A&E attendance admitted	xx.xx (xx)	xx.xx (xx)	
Inpatient admission	xx.xx (xx)	xx.xx (xx)	
Critical care admission	xx.xx (xx)	xx.xx (xx)	
Missing (n/(%))	xx (xx)	xx (xx)	

Table 7: Intervention costs (2019/20 £)

	Unit cost	Units	Cost	Source
Usual Care				
Component1	xx.xx	xx	xx.xx	
Component 2	xx.xx	XX	xx.xx	
Total cost			xx.xx	
Treatment A				
Component1	xx.xx	XX	XX.XX	
Component 2	xx.xx	xx	xx.xx	
Total cost			xx.xx	

Table 8: Total healthcare resource use costs at 60 days post randomisation

	Usual Care Group	Intervention Group	Adjusted effect estimate (95% CI)	ICC
Treatment A	(n =)	(n =)		
Total intervention costs	xx.xx (xx)	xx.xx (xx)		
Resource use item (mean, sd)				
GP face-to-face	xx.xx (xx)	xx.xx (xx)		
GP remote	xx.xx (xx)	xx.xx (xx)		
Nurse face-to-face	xx.xx (xx)	xx.xx (xx)		
Nurse remote	xx.xx (xx)	xx.xx (xx)		
Nurse Specialist face-to-face	xx.xx (xx)	xx.xx (xx)		
Nurse Specialist remote	xx.xx (xx)	xx.xx (xx)		
Allied Health Professional face-to-face	xx.xx (xx)	xx.xx (xx)		
Allied Health Professional remote	xx.xx (xx)	xx.xx (xx)		
Outpatient/hospital doctor	xx.xx (xx)	xx.xx (xx)		
111 Call	xx.xx (xx)	xx.xx (xx)		
999 Call	xx.xx (xx)	xx.xx (xx)		
Ambulance attendance	xx.xx (xx)	xx.xx (xx)		
A&E attendance non-admitted	xx.xx (xx)	xx.xx (xx)		
A&E attendance admitted	xx.xx (xx)	xx.xx (xx)		
Inpatient admission	xx.xx (xx)	xx.xx (xx)		
Critical care admission	xx.xx (xx)	xx.xx (xx)		
Total costs (mean, sd)	xx (xx)	xx(xx)	xx (xx.x to xx.x)	0.xxx

Figure 3: Healthcare resource use costs at 60 days post randomisation

Histogram of costs by group

Table 9: Cost-effectiveness at 60 days post randomisation

	Usual Care Group	Intervention Group	Adjusted effect	ICC
			estimate	
			(95% CI)	
Treatment A	(n =)	(n =)		
Quality Adjusted Life Years (QALYs)				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25th, 75th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	XX	xx		
Healthcare resource use costs				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25th, 75th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	XX	XX		
Incremental cost-effectiveness ratio (cost per			x (xx.x to xx.x)	0.xxx
QALY)				
Incremental net monetary benefit (INMB)				
k=£15,000			x (xx.x to xx.x)	0.xxx
k=£20,000			x (xx.x to xx.x)	0.xxx
k=£30,000			x (xx.x to xx.x)	0.xxx

Figure 4: Cost-effectiveness plane
Scatterplot of costs/effects

Figure 5: Cost-effectiveness acceptability curve

Line graph of probability of cost-effectiveness at different willingness to pay.

Table 10: Cost-effectiveness at 120 days post randomisation

	Usual Care Group	Intervention Group	Adjusted effect estimate (95% CI)	ICC
Treatment A	(n =)	(n =)		
Quality Adjusted Life Years (QALYs)				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25th, 75th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	XX	XX		
Healthcare resource use costs				
Mean[sd]	xx (xx)	xx (xx)	xx (xx.x to xx.x)	0.xxx
Median [25 th , 75 th centile]	xx (xx to xx)	xx (xx to xx)		
Min, max	xx to xx	xx to xx		
Missing	XX	xx		
Incremental net monetary benefit (INMB)				
k=£15,000			x (xx.x to xx.x)	0.xxx
k=£20,000			x (xx.x to xx.x)	0.xxx
k=£30,000			x (xx.x to xx.x)	0.xxx